propidium iodide has been researched along with donepezil in 10 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 4 (40.00) | 29.6817 |
| 2010's | 5 (50.00) | 24.3611 |
| 2020's | 1 (10.00) | 2.80 |
| Authors | Studies |
|---|---|
| Andrisano, V; Bartolini, M; Bidon-Chanal, A; de Austria, C; del Monte-Millán, M; Dorronsoro, I; García-Palomero, E; Luque, FJ; Martínez, A; Medina, M; Muñoz-Ruiz, P; Orozco, M; Rubio, L; Usán, P; Valenzuela, R | 1 |
| Andrisano, V; Banzi, R; Bartolini, M; Bergamini, C; Bolognesi, ML; Cattaneo, A; Cavalli, A; Fato, R; Hrelia, P; Lenaz, G; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tarozzi, A; Tumiatti, V | 1 |
| Bolognesi, ML; Cavalli, A; Melchiorre, C; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V | 1 |
| Andrisano, V; Bartolini, M; Bolognesi, ML; Cavalli, A; Mancini, F; Melchiorre, C; Micco, M; Milelli, A; Minarini, A; Recanatini, M; Rosini, M; Tumiatti, V | 1 |
| Lv, W; Xue, Y | 1 |
| Andrisano, V; Bartolini, M; Belluti, F; Bisi, A; Bottegoni, G; Cavalli, A; Rampa, A | 1 |
| Bolea, I; Chioua, M; de Los Ríos, C; Juárez-Jiménez, J; Luque, FJ; Marco-Contelles, J; Pouplana, R; Samadi, A; Unzeta, M | 1 |
| Beazely, MA; Mohamed, T; Rao, PP; Vasefi, MS; Yeung, JC | 1 |
| Azzouz, R; Bohn, P; Gembus, V; Levacher, V; Papamicaël, C; Peauger, L; Sopková-de Oliveira Santos, J; Ţînţaş, ML | 1 |
| Andrisano, V; Arce, EM; Barenys, M; Bartolini, M; Bolognesi, ML; Brea, J; De Simone, A; Decker, M; Ginex, T; Gómez-Catalán, J; Griñán-Ferré, C; Loza, MI; Luque, FJ; Martínez, N; Mattellone, A; Muñoz-Torrero, D; Naldi, M; Pallàs, M; Pérez, B; Pont, C; Sabate, R; Scheiner, M; Soriano-Fernández, Y | 1 |
1 review(s) available for propidium iodide and donepezil
| Article | Year |
|---|---|
Multi-target-directed ligands to combat neurodegenerative diseases.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Calcium Channel Blockers; Chelating Agents; Cholinesterase Inhibitors; Humans; Huntington Disease; Ligands; Multiple Sclerosis; Neurodegenerative Diseases; Neurofibrillary Tangles; Neurotransmitter Agents; Parkinson Disease; Plaque, Amyloid | 2008 |
9 other study(ies) available for propidium iodide and donepezil
| Article | Year |
|---|---|
Design, synthesis, and biological evaluation of dual binding site acetylcholinesterase inhibitors: new disease-modifying agents for Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Butyrylcholinesterase; Cattle; Cell Line, Tumor; Cholinesterase Inhibitors; Dimerization; Drug Design; Erythrocytes; Fluorometry; Humans; Models, Molecular; Nootropic Agents; Protein Binding; Structure-Activity Relationship; Tacrine | 2005 |
Novel class of quinone-bearing polyamines as multi-target-directed ligands to combat Alzheimer's disease.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Antioxidants; Binding Sites; Butyrylcholinesterase; Cell Line; Cholinesterase Inhibitors; Humans; Ligands; Models, Molecular; NAD(P)H Dehydrogenase (Quinone); Oxidative Stress; Polyamines; Protein Binding; Quinones; Reactive Oxygen Species; Structure-Activity Relationship; Substrate Specificity | 2007 |
Structure-activity relationships of acetylcholinesterase noncovalent inhibitors based on a polyamine backbone. 4. Further investigation on the inner spacer.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Cholinesterase Inhibitors; Drug Design; Ligands; Molecular Structure; Polyamines; Stereoisomerism; Structure-Activity Relationship | 2008 |
Prediction of acetylcholinesterase inhibitors and characterization of correlative molecular descriptors by machine learning methods.
Topics: Algorithms; Artificial Intelligence; Cholinesterase Inhibitors; Computational Biology; Drug Design; Models, Chemical; Quantitative Structure-Activity Relationship | 2010 |
Benzophenone-based derivatives: a novel series of potent and selective dual inhibitors of acetylcholinesterase and acetylcholinesterase-induced beta-amyloid aggregation.
Topics: Acetylcholinesterase; Amyloid beta-Peptides; Benzophenones; Cholinesterase Inhibitors; Humans; Models, Molecular; Molecular Dynamics Simulation; Molecular Structure; Monte Carlo Method; Peptide Fragments; Stereoisomerism; Structure-Activity Relationship | 2011 |
Synthesis, biological evaluation, and molecular modeling of donepezil and N-[(5-(benzyloxy)-1-methyl-1H-indol-2-yl)methyl]-N-methylprop-2-yn-1-amine hybrids as new multipotent cholinesterase/monoamine oxidase inhibitors for the treatment of Alzheimer's di
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid beta-Peptides; Animals; Binding Sites; Butyrylcholinesterase; Cholinesterase Inhibitors; Donepezil; Electrophorus; Horses; Humans; Indans; Indoles; Isoenzymes; Kinetics; Models, Molecular; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Peptide Fragments; Piperidines; Rats; Structure-Activity Relationship | 2011 |
Development and evaluation of multifunctional agents for potential treatment of Alzheimer's disease: application to a pyrimidine-2,4-diamine template.
Topics: Alzheimer Disease; Amyloid beta-Peptides; Cell Line, Tumor; Cell Survival; Diamines; Humans; Models, Molecular; Molecular Structure; Pyrimidines; Retinoblastoma; Structure-Activity Relationship | 2012 |
Donepezil-Based Central Acetylcholinesterase Inhibitors by Means of a "Bio-Oxidizable" Prodrug Strategy: Design, Synthesis, and in Vitro Biological Evaluation.
Topics: Acetylcholinesterase; Alzheimer Disease; Amyloid; Animals; Cholinesterase Inhibitors; Donepezil; Drug Design; Female; Humans; Indans; Mice; Molecular Docking Simulation; Piperidines; Prodrugs | 2017 |
From virtual screening hits targeting a cryptic pocket in BACE-1 to a nontoxic brain permeable multitarget anti-Alzheimer lead with disease-modifying and cognition-enhancing effects.
Topics: Alzheimer Disease; Aminoquinolines; Amyloid beta-Peptides; Amyloid Precursor Protein Secretases; Aspartic Acid Endopeptidases; Brain; Dose-Response Relationship, Drug; Drug Evaluation, Preclinical; Heterocyclic Compounds, 4 or More Rings; Humans; Molecular Dynamics Simulation; Molecular Structure; Neuroprotective Agents; Recombinant Proteins; Structure-Activity Relationship; tau Proteins | 2021 |